Business context and reporting period
The supplied filing is GlycoMimetics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2017, filed May 8, 2017. This does not match the request metadata naming Crescent BioPharma, Inc.; verify the issuer before relying on this summary. GlycoMimetics is a clinical-stage biotechnology company developing glycomimetic drug candidates and has no commercial products.
Financial performance and position
| Metric | Q1 2017 / March 31, 2017 | Comparable period / prior year-end |
|---|---|---|
| Revenue | $0 | $0 in Q1 2016 |
| Research and development expense | $5.88 million | $5.52 million in Q1 2016 |
| General and administrative expense | $2.09 million | $2.06 million in Q1 2016 |
| Net loss | $7.93 million; $0.34 per share | $7.55 million; $0.40 per share in Q1 2016 |
| Operating cash flow | $(9.06) million | $(9.23) million in Q1 2016 |
| Cash and cash equivalents | $34.59 million | $40.04 million at Dec. 31, 2016 |
| Total assets / liabilities | $37.17 million / $5.29 million | $42.39 million / $7.09 million at Dec. 31, 2016 |
No debt is reported in the presented balance sheet. The company reported no product revenue, so a revenue margin is not meaningful. Cash used in investing was $0.06 million; financing provided $3.67 million, primarily from at-the-market share sales. Cash declined by $5.45 million during the quarter.
Material changes versus the prior comparable period
- Net loss increased by $0.38 million (about 5%); operating expenses rose by $0.40 million. R&D increased 7%, mainly from ongoing GMI-1271 clinical-trial costs and higher personnel and stock compensation, partly offset by lower manufacturing and process-development expense.
- R&D by candidate: GMI-1271 expense rose to $3.01 million from $2.07 million; GMI-1359 fell to $0.16 million from $1.06 million.
- Loss per share narrowed to $0.34 from $0.40, while weighted-average shares increased to 23.48 million from 19.07 million.
- Quarterly operating cash use was slightly lower than in Q1 2016. The company raised $3.7 million net through its ATM facility in Q1; after quarter-end it sold another 784,416 shares for $3.8 million net, diluting existing holders.
Outlook, commentary, and risks
- Management expected March 31 cash, plus interest, to fund operating expenses and capital needs into the second quarter of 2018. This estimate depends on assumptions that may prove inaccurate.
- Management expects significant expenses and operating losses to continue, with R&D spending expected to rise as clinical programs advance. The company may need additional equity, debt, or collaboration funding; financing may be unavailable or dilutive.
- GMI-1271: the company completed enrollment of 25 patients in the newly diagnosed AML cohort aged 60 or older in March 2017 and expected to complete enrollment of the relapsed/refractory cohort in mid-2017. It planned further study updates during 2017. Earlier interim results cited response rates of 45% in 33 relapsed/refractory patients and 73% in 11 older newly diagnosed patients; these are preliminary clinical data, not established efficacy.
- GMI-1271 is also being studied with chemotherapy for multiple myeloma. GMI-1359 had completed enrollment through a 2 mg/kg dose in a Phase 1 healthy-volunteer study in 2016. The company planned further preclinical work on galectin-3 inhibitors during 2017.
- Pfizer holds the worldwide rivipansel license and is responsible for further development and commercialization. Future milestone and royalty receipts are contingent and uncertain; none were recognized in Q1 2017. Potential royalties and milestones depend on clinical, regulatory, and commercial outcomes. The University of Basel is entitled to 10% of future Pfizer milestone and royalty receipts for rivipansel.
- Key risks include clinical-trial enrollment and outcomes, regulatory approval, manufacturing, intellectual-property protection, competition, and the need for further financing. The filing reported no material legal proceedings, no material change to previously disclosed risk factors, and effective disclosure controls.
Important facts for investors to verify
- Confirm the issuer: the filing is for GlycoMimetics, Inc., not Crescent BioPharma, Inc.
- Check subsequent cash use, ATM share issuance, and whether the stated runway into Q2 2018 remains current.
- Review updated GMI-1271 clinical results and trial status, including the limitations of the interim response-rate data.
- Verify Pfizer’s rivipansel development progress and the conditions and timing for any future milestones or royalties.
- Assess the need, availability, and dilution impact of future financing as operating losses continue.